Title : Effects of Ado-Trastuzumab Emtansine and Fam-Trastuzumab Deruxtecan on Metastatic Breast Cancer Harboring HER2 Amplification and the L755S Mutation.

Pub. Date : 2021 Aug

PMID : 33559918






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Some HER2 mutations are activating, and they represent a mechanism of resistance to conventional anti-HER2 therapies such as trastuzumab and lapatinib. Lapatinib erb-b2 receptor tyrosine kinase 2 Homo sapiens
2 Some HER2 mutations are activating, and they represent a mechanism of resistance to conventional anti-HER2 therapies such as trastuzumab and lapatinib. Lapatinib erb-b2 receptor tyrosine kinase 2 Homo sapiens
3 A case of de novo metastatic breast cancer harboring both HER2 amplification and the L755S mutation in an untreated breast primary tumor displayed clinical resistance to standard trastuzumab- or lapatinib-based therapies but good responses to T-DM1 and T-DXd. Lapatinib erb-b2 receptor tyrosine kinase 2 Homo sapiens